NASDAQ: CRVOCervomed Inc Stock
$2.53-0.04 (-1.56%)
Updated Sep 14, 2026
CRVO Price
$2.53
Fair Value Price
$0.91
Market Cap
$38.25M
52 Week Low
$2.15
52 Week High
$10.00
P/E
-0.79x
P/B
1.67x
P/S
95.86x
PEG
N/A
Dividend Yield
N/A
Revenue
$331.30k
Earnings
-$30.35M
Gross Margin
100%
Operating Margin
-9,160.94%
Profit Margin
-9,160.9%
Debt to Equity
0.13
Operating Cash Flow
-$28M
Beta
0.99
Next Earnings
Nov 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
CRVO Overview
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CRVO's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CRVO
Ranked#316 of 459
Ranked#316 of 459
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.14 | A | |
| $6.85 | A | |
| $41.54 | A |
Be the first to know about important CRVO news, forecast changes, insider trades & much more!
CRVO News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CRVO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CRVO ($2.53) is overvalued by 177.77% relative to our estimate of its Fair Value price of $0.91 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CRVO ($2.53) is not significantly undervalued (177.77%) relative to our estimate of its Fair Value price of $0.91 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CRVO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CRVO due diligence checks available for Premium users.
Valuation
CRVO fair value
Fair Value of CRVO stock based on Discounted Cash Flow (DCF)
Price
$2.53
Fair Value
$0.91
Overvalued by
177.77%
CRVO ($2.53) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CRVO ($2.53) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CRVO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CRVO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.79x
Industry
8.25x
Market
43.6x
CRVO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.67x
Industry
5.35x
CRVO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CRVO's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.6M
Profit Margin
0%
CRVO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CRVO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$26.0M
Liabilities
$3.0M
Debt to equity
0.13
CRVO's short-term assets ($25.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CRVO's short-term assets ($25.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CRVO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CRVO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.9M
Investing
$2.5M
Financing
$18.9M
CRVO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CRVO vs Biotech Stocks
Cervomed Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.